Professor Lee Han-seung looked at Kim Do-yoon and asked.
“Master Kim? Why, Mr. Kim?”
“As you know, there are issues of stability and efficiency in the movement of mesenchymal stem cell therapeutics to damaged tissues.”
“Oh, yes. But isn’t NTX-3 going into late phase 2 clinical trials because the problem did not occur?”
“That is the case. Anyway, Mr. Kim Do-yoon over there solved the problem completely.”
“You solved it, what… … ?”
President Kang briefly explained how Kim Do-yoon came up with it.
“Oh, that way… … . We’ll have to listen to the details, but it sounds plausible. It’s microporation… … . Hmm… … .”
Stem cell therapy has shown the potential to cure many neurological diseases known for which there are no special drugs because of its breakthrough efficacy.
Professor Hanseung
